The call highlighted strong financial performance, significant growth in key product segments, and successful strategic initiatives, despite ongoing market competition and operational challenges in onboarding new accounts.

Company Guidance -

Q2 2025

During the Heron Therapeutics Q1 2025 earnings call, the company reported total net revenues of approximately $39 million, achieving a record quarterly adjusted EBITDA of $6.2 million and a net income of $2.6 million. The oncology franchise, including CINVANTI and SUSTOL, generated combined net revenues of $28.6 million, despite a competitive market. Heron's gross profit margin for the quarter was 78%, attributed to production efficiencies and increased sales volumes. G&A expenses decreased to $25 million from the previous year, while research and development expenses were reduced to $2.3 million. The company revised its adjusted EBITDA guidance range to $4 million to $12 million, up from the previous range of $0 to $8 million. Heron emphasized its focus on disciplined execution and optimizing commercial performance, particularly for its key products ZYNRELEF and APONVIE, which saw significant growth in Q1 2025.

Significant Revenue Growth

Heron Therapeutics generated total net revenues of approximately $39 million for Q1 2025, with a record quarterly adjusted EBITDA of $6.2 million and net income of $2.6 million, highlighting a strong financial performance.

Oncology Franchise Success

Combined net revenues from CINVANTI and SUSTOL reached $28.6 million for the quarter, maintaining market share in a competitive environment and demonstrating strong product performance.

Strong Product Growth in Acute Hospital Segment

APONVIE and ZYN experienced significant growth in Q1 2025, up over 432% and 60%, respectively, compared to the same period last year, indicating strong market adoption.

Improved Financial Metrics

Product gross profit for Q1 2025 was $30.4 million or 78%, an increase from 76% in the same period in 2024, due to production efficiencies.

Revised Positive Financial Guidance

The company revised its adjusted EBITDA guidance from a range of $0 to $8 million to a range of $4 million to $12 million.

Heron Therapeutics (HRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HRTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 11, 2025	2025 (Q2)	-0.01 / -	-0.06	―	―	―
May 06, 2025	2025 (Q1)	>-0.01 / 0.01	-0.02	150.00% (+0.03)
Feb 27, 2025	2024 (Q4)	-0.03 / 0.02	-0.07	128.57% (+0.09)
Nov 12, 2024	2024 (Q3)	-0.04 / -0.03	-0.17	82.35% (+0.14)
Aug 06, 2024	2024 (Q2)	-0.04 / -0.06	-0.35	82.86% (+0.29)
May 07, 2024	2024 (Q1)	-0.07 / -0.02	-0.27	92.59% (+0.25)
Mar 12, 2024	2023 (Q4)	-0.15 / -0.07	-0.17	58.82% (+0.10)
Nov 14, 2023	2023 (Q3)	-0.29 / -0.17	-0.38	55.26% (+0.21)
Aug 14, 2023	2023 (Q2)	-0.22 / -0.35	-0.55	36.36% (+0.20)
May 11, 2023	2023 (Q1)	-0.22 / -0.27	-0.63	57.14% (+0.36)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HRTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$2.13	$2.42	+13.62%
Feb 27, 2025	$1.71	$2.05	+19.88%
Nov 12, 2024	$1.84	$1.28	-30.43%
Aug 06, 2024	$2.67	$2.00	-25.09%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.